Safety and Efficacy of Long‐Term Treatment of Type 1 Plasminogen Deficient Patients With Intravenous Plasminogen Replacement Therapy
Haemophilia · 2025
DOI: 10.1111/hae.70019 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Haemophilia, 2025. Verfasst von Amy D Shapiro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Blood Coagulation Disorders, Inherited, Plasminogen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kedrion Biopharma, Inc..
Abstract (Originalsprache)
Introduction
Type 1 plasminogen deficiency (PLGD‐1), or hypoplasminogenaemia, is an ultra‐rare autosomal‐recessive disorder characterised by fibrin‐rich lesions on mucous membranes, often leading to serious complications if left untreated. Prior treatments have shown limited and inconsistent success, but IV PLG concentrate (Ryplazim) offers a targeted therapy.
Aim
This study investigated the long‐term safety and efficacy of IV PLG concentrate treatment for PLGD‐1 patients.
Methods
A long‐term study (NCT03642691) followed 12 participants who had previously been included in pivotal or expanded access trials of IV PLG concentrate. Participants received 6.6 mg/kg IV PLG concentrate infusions, with dosing frequency adjusted based on clinical response and plasminogen levels. Safety assessments and plasminogen level measurements were conducted.
Results
The median treatment duration during this long‐term follow‐up study was 41 months (range: 25–42 months). The median total exposure for participants in this study throughout the clinical development was 68 months (range: 28–71 months). No new or recurring ligneous lesions occurred when participants adhered to the prescribed regimen. Temporary disruptions in the drug supply led to some lesion recurrences, which resolved upon resuming the prescribed dosing frequency. A total of 2165 infusions were administered in this study, and most adverse events were mild. No anti‐plasminogen antibodies or treatment‐related fatalities occurred.
Conclusion
Long‐term treatment with IV PLG concentrate is safe and effective for PLGD‐1, demonstrating the potential for tailored dosing regimens. This study highlights the importance of individualised treatment and provides valuable insights into managing this ultra‐rare disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, USA.
- Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Consultant to Kedrion Biopharma, Fort Lee, New Jersey, USA.
- Global Medical Affairs, Kedrion S.p.A, Laval, Quebec, Canada.
ORCID-Profile: Amy D Shapiro, Charles Nakar, Jeremy Lorber, Karen Thibaudeau
Förderung
- Kedrion Biopharma, Inc.
Zitieren
APA
Shapiro, A. D., McDaniel, H., Decker, R. W., Nakar, C., Lorber, J., Thukral, N., Parker, J. M., & Thibaudeau, K. (2025). Safety and Efficacy of Long‐Term Treatment of Type 1 Plasminogen Deficient Patients With Intravenous Plasminogen Replacement Therapy. Haemophilia. https://doi.org/10.1111/hae.70019
Vancouver
Shapiro AD, McDaniel H, Decker RW, Nakar C, Lorber J, Thukral N, et al. Safety and Efficacy of Long‐Term Treatment of Type 1 Plasminogen Deficient Patients With Intravenous Plasminogen Replacement Therapy. Haemophilia. 2025. doi:10.1111/hae.70019
BibTeX
@article{Shapiro2025,
author = {Shapiro, Amy D and McDaniel, Heather and Decker, Robert W and Nakar, Charles and Lorber, Jeremy and Thukral, Neelam and Parker, Joseph M and Thibaudeau, Karen},
title = {Safety and Efficacy of Long‐Term Treatment of Type 1 Plasminogen Deficient Patients With Intravenous Plasminogen Replacement Therapy},
journal = {Haemophilia},
year = {2025},
doi = {10.1111/hae.70019}
}
EUVIMED